Skip to content

Super dose Lucentis study reports visual acuity gains and anatomic improvements

A clinical study designed to test a higher dose of intravitreal ranibizumab (Lucentis) on neovascular age-related macular degeneration (AMD) patients with persistent disease activity has reported statistically significant visual acuity (VA) gains. The study, led by the SAVE [Super-dose Anti-VEGF] Study Group had hypothesized that a higher dose (2.0 mg versus the approved 0.5 mg) may show improved efficacy based on the original dose dependent findings of the published MARINA and ANCHOR clinical trials. The 3-month SAVE data will need to be followed out to 24 months to determine whether or not the initial gains are sustained.